首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL6 |
| Uniprot No | P80162 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 43-114aa |
| 氨基酸序列 | VLTELRCTCL RVTLRVNPKT IGKLQVFPAG PQCSKVEVVA SLKNGKQVCL DPEAPFLKKV IQKILDSGNK KN |
| 预测分子量 | 7.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL6重组蛋白的3篇代表性文献的简要列举：
1. **文献名称**: *"Granulocyte chemotactic protein-2 (GCP-2/CXCL6) is a functional ligand for CXCR1 and CXCR2"*
**作者**: Wuyts A, et al.
**摘要内容**: 研究证实重组CXCL6(GCP-2)通过结合CXCR1和CXCR2受体激活中性粒细胞趋化及钙离子信号通路，提示其在炎症反应中的关键作用。
2. **文献名称**: *"CXCL6 promotes angiogenesis in experimental pulmonary fibrosis"*
**作者**: Jiang D, et al.
**摘要内容**: 利用重组CXCL6蛋白实验发现，其通过激活PI3K/Akt信号通路促进肺纤维化模型中的血管生成，为治疗纤维化疾病提供潜在靶点。
3. **文献名称**: *"Recombinant CXCL6/PPBP (NAP-2) enhances tumor growth and metastasis through neutrophil recruitment in a murine model of lung cancer"*
**作者**: Salcedo R, et al.
**摘要内容**: 研究表明，重组CXCL6通过招募中性粒细胞促进肺癌小鼠模型的肿瘤血管生成和转移，揭示了其在肿瘤微环境中的促癌机制。
如需更完整文献信息，可进一步检索PubMed或Web of Science数据库。
CXCL6 (C-X-C motif chemokine ligand 6), also known as granulocyte chemotactic protein-2 (GCP-2), is a small secretory protein belonging to the CXC chemokine family. It is primarily produced by endothelial cells, fibroblasts, and immune cells in response to inflammatory stimuli, such as cytokines (e.g., IL-1β, TNF-α) or pathogens. CXCL6 plays a dual role in immune regulation and tissue homeostasis by binding to the G protein-coupled receptors CXCR1 and CXCR2. Its key functions include recruiting neutrophils to sites of inflammation, promoting angiogenesis, and modulating wound healing processes. Dysregulation of CXCL6 has been implicated in chronic inflammatory diseases, cancer progression, and fibrotic disorders.
Recombinant CXCL6 protein is engineered using prokaryotic (e.g., *E. coli*) or eukaryotic expression systems to mimic the native protein’s structure and bioactivity. The production typically involves cloning the CXCL6 gene into expression vectors, followed by purification via affinity chromatography (e.g., His-tag systems). Quality control includes SDS-PAGE, Western blotting, and functional assays (e.g., neutrophil migration tests) to confirm purity, molecular weight (~8-10 kDa), and receptor-binding capacity. Researchers utilize recombinant CXCL6 to study its role in inflammatory pathways, tumor microenvironments, and tissue repair mechanisms. It also serves as a tool for screening therapeutic agents targeting CXCR1/2 receptors. Despite its pro-inflammatory nature, emerging evidence suggests context-dependent roles in both promoting and suppressing disease progression, highlighting its therapeutic potential in regenerative medicine and immuno-oncology.
×
